Country: Canada
Language: English
Source: Health Canada
CETIRIZINE HYDROCHLORIDE
MARCAN PHARMACEUTICALS INC
R06AE07
CETIRIZINE
10MG
TABLET
CETIRIZINE HYDROCHLORIDE 10MG
ORAL
30/100/500
OTC
SECOND GENERATION ANTIHISTAMINES
Active ingredient group (AIG) number: 0122686001; AHFS:
APPROVED
2016-06-29
IPG-CETIRIZINE - Product Monograph Page 1 of 34 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION IPG-CETIRIZINE Cetirizine Hydrochloride Tablets Tablets, 5 mg, 10 mg, Oral Histamine H 1 Receptor Antagonist Marcan Pharmaceuticals Inc. 2 Gurdwara Road, Suite #112 Ottawa, ON, K2E 1A2 Date of Initial Authorization: JUN 06, 2014 Date of Revision: JAN 24, 2023 Submission Control Number: 267528 IPG-CETIRIZINE - Product Monograph Page 2 of 34 RECENT MAJOR LABEL CHANGES N/A TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES .............................................................................................2 TABLE OF CONTENTS ...............................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION .......................................................................4 1 INDICATIONS ...............................................................................................................4 1.1 Pediatrics ...........................................................................................................4 1.2 Geriatrics............................................................................................................4 2 CONTRAINDICATIONS ..................................................................................................4 4 DOSAGE AND ADMINISTRATION ..................................................................................4 4.1 Dosing Considerations.........................................................................................4 4.2 Recommended Dose and Dosage Adjustment......................................................4 4.4 Administration....................................................................................................5 4.5 Missed Dose .......................................................................................................5 5 OVERDOSAGE ............... Read the complete document